Pieris Pharmaceuticals, Inc.
Symbol: PIRS
NASDAQ
11.08
USDTrhová cena dnes
-0.5788
Pomer P/E
0.0000
Pomer PEG
13.70M
MRK Cap
- 0.00%
Výnos DIV
Pieris Pharmaceuticals, Inc. (PIRS) Finančné výkazy
Súvaha
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 174.43 | 26.4 | 59.2 | 117.8 | |||||||||||
balance-sheet.row.short-term-investments | 39.46 | 9 | 20.5 | 0 | |||||||||||
balance-sheet.row.net-receivables | 11.07 | 6 | 5.8 | 3.3 | |||||||||||
balance-sheet.row.inventory | 2.1 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-current-assets | 37.14 | 6.3 | 8.4 | 6.5 | |||||||||||
balance-sheet.row.total-current-assets | 224.75 | 38.7 | 73.4 | 127.6 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 42.47 | 0 | 20.7 | 23 | |||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-non-current-assets | 0.65 | 0 | 1.4 | 2.9 | |||||||||||
balance-sheet.row.total-non-current-assets | 43.11 | 0 | 22.1 | 25.9 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 267.86 | 38.7 | 95.5 | 153.6 | |||||||||||
balance-sheet.row.account-payables | 22.5 | 3.4 | 4.2 | 8.6 | |||||||||||
balance-sheet.row.short-term-debt | 14.09 | 0 | 0.9 | 1 | |||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-debt-total | 24.12 | 0 | 12.2 | 13.8 | |||||||||||
Deferred Revenue Non Current | 12.49 | 0 | 18.7 | 38.4 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | -12.49 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 36.07 | 8.6 | 10.7 | 15.8 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 36.6 | 0 | 31 | 52.2 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 37.32 | 0 | 12.2 | 13.8 | |||||||||||
balance-sheet.row.total-liab | 154.63 | 11.9 | 67.6 | 102.8 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0.37 | 0.1 | 0.1 | 0.1 | |||||||||||
balance-sheet.row.retained-earnings | -1228.58 | -315 | -290.4 | -257.1 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -0.87 | 0 | -0.3 | 0.8 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 1342.3 | 341.6 | 318.5 | 307 | |||||||||||
balance-sheet.row.total-stockholders-equity | 113.22 | 26.8 | 27.9 | 50.8 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 267.86 | 38.7 | 95.5 | 153.6 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 113.22 | 26.8 | 27.9 | 50.8 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 267.86 | - | - | - | |||||||||||
Total Investments | 39.46 | 9 | 20.5 | 0 | |||||||||||
balance-sheet.row.total-debt | 37.32 | 0 | 13.1 | 13.8 | |||||||||||
balance-sheet.row.net-debt | -97.65 | -17.4 | -25.5 | -103.9 |
Výkaz peňažných tokov
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -24.54 | -24.5 | -33.3 | -45.7 | |||||||||||
cash-flows.row.depreciation-and-amortization | 1.81 | 1.8 | 2.8 | 2.4 | |||||||||||
cash-flows.row.deferred-income-tax | 14.53 | -4.5 | 0 | 0 | |||||||||||
cash-flows.row.stock-based-compensation | 3.35 | 3.3 | 4.4 | 5.2 | |||||||||||
cash-flows.row.change-in-working-capital | -48.14 | -48.1 | -33.4 | 30.5 | |||||||||||
cash-flows.row.account-receivables | 5.31 | 5.3 | -2.6 | -1.8 | |||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 5.7 | |||||||||||
cash-flows.row.account-payables | -0.79 | -0.8 | -4.2 | 7 | |||||||||||
cash-flows.row.other-working-capital | -12.71 | -52.7 | -26.5 | 19.6 | |||||||||||
cash-flows.row.other-non-cash-items | -0.82 | 18.3 | -0.5 | 0 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -53.82 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.17 | -0.2 | -1 | -0.9 | |||||||||||
cash-flows.row.acquisitions-net | -12.17 | 0 | 20.2 | 0 | |||||||||||
cash-flows.row.purchases-of-investments | -22.84 | -22.8 | -48.4 | 0 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 35.01 | 35 | 28.2 | 0 | |||||||||||
cash-flows.row.other-investing-activites | 12.17 | 0 | -20.2 | 0 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 12 | 12 | -21.2 | -0.9 | |||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -1 | 0 | |||||||||||
cash-flows.row.common-stock-issued | 19.74 | 19.8 | 6.9 | 57.1 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-financing-activites | 0.07 | 0.1 | 1.3 | 2 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 19.8 | 19.8 | 7.2 | 59.1 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.78 | 0.8 | -5.2 | -3.2 | |||||||||||
cash-flows.row.net-change-in-cash | -21.24 | -21.2 | -79.1 | 47.3 | |||||||||||
cash-flows.row.cash-at-end-of-period | 134.97 | 17.4 | 38.6 | 117.8 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 156.21 | 38.6 | 117.8 | 70.4 | |||||||||||
cash-flows.row.operating-cash-flow | -53.82 | -53.8 | -59.9 | -7.7 | |||||||||||
cash-flows.row.capital-expenditure | -0.17 | -0.2 | -1 | -0.9 | |||||||||||
cash-flows.row.free-cash-flow | -53.99 | -54 | -61 | -8.6 |
Riadok výkazu ziskov a strát
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 42.81 | 42.8 | 25.9 | 31.4 | |||||||||||
income-statement-row.row.cost-of-revenue | 6.49 | 1.8 | 2.8 | 2.4 | |||||||||||
income-statement-row.row.gross-profit | 36.32 | 41 | 23.1 | 29.1 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 41.8 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 16.85 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 13.91 | 13.9 | -8.2 | -3.7 | |||||||||||
income-statement-row.row.operating-expenses | 55.04 | 56.9 | 61.2 | 79.6 | |||||||||||
income-statement-row.row.cost-and-expenses | 55.04 | 58.7 | 61.2 | 79.6 | |||||||||||
income-statement-row.row.interest-income | 1.85 | 1.9 | 0.7 | 0 | |||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -10.2 | 0 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -11.32 | -8.7 | 10.2 | 6.1 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 13.91 | 13.9 | -8.2 | -3.7 | |||||||||||
income-statement-row.row.total-operating-expenses | -11.32 | -8.7 | 10.2 | 6.1 | |||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -10.2 | 0 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 3.94 | 1.8 | 8.2 | 3.7 | |||||||||||
income-statement-row.row.ebitda-caps | 3.87 | - | - | - | |||||||||||
income-statement-row.row.operating-income | -30.74 | -15.8 | -43.5 | -51.8 | |||||||||||
income-statement-row.row.income-before-tax | -24.54 | -24.5 | -33.3 | -45.7 | |||||||||||
income-statement-row.row.income-tax-expense | 12.28 | 0 | -2 | -2.4 | |||||||||||
income-statement-row.row.net-income | -23.67 | -24.5 | -31.3 | -43.4 |
Často kladené otázky
Čo je Pieris Pharmaceuticals, Inc. (PIRS) celkové aktíva?
Pieris Pharmaceuticals, Inc. (PIRS) celkové aktíva sú 38680000.000.
Aký je ročný obrat podniku?
Ročné príjmy sú 20819000.000.
Aké je ziskové rozpätie podniku?
Zisková marža firmy je 0.848.
Aký je voľný peňažný tok podniku?
Voľný peňažný tok je -43.657.
Aká je čistá zisková marža podniku?
Čistá zisková marža je -0.553.
Aké sú celkové výnosy podniku?
Celkové príjmy sú -0.718.
Aká je Pieris Pharmaceuticals, Inc. (PIRS) čistý zisk (čistý príjem)?
Čistý zisk (čistý príjem) je -24543000.000.
Aký je celkový dlh firmy?
Celkový dlh je 0.000.
Aké je číslo prevádzkových nákladov?
Prevádzkové výdavky sú 56873000.000.
Aký je údaj o hotovosti spoločnosti?
Peňažné prostriedky podniku sú 17396000.000.